MedTrace Logo

D-cycloserine for the Treatment of Chronic, Refractory Low Back Pain

NCT03535688 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 203

Last updated 2026-05-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of D-cycloserine versus placebo in relieving the signs and symptoms of patients with chronic lower back pain.

Conditions

  • Low Back Pain
  • Pain

Interventions

DRUG

D-cycloserine

200 mg twice daily

DRUG

Placebo

twice daily

Sponsors & Collaborators

Principal Investigators

  • Thomas J. Schnitzer, MD, PhD · Northwestern University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-30
Primary Completion
2024-02-07
Completion
2024-02-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03535688 on ClinicalTrials.gov